Radium Ra223 dichloride

二氯化镭[223Ra]

Report date: 2026/02/24 20:00:16
First In Class

Base Information

Drug NameRadium Ra223 dichloride
Drug Alias Name二氯化镭RADIUM RA-223 DICHLORIDE镭-223二氯化合物Radium Ra 223 dichlorideRadium-223 dichloride +[16] 
ClassificationSmall molecules > Inorganic and minerals saltRadiation-emitting products > Nuclides > Radium > 223Ra
Mechanisms of ActionIonising radiation emitters
TargetsNot applicable
Therapy Area/IndicationsBone metastasesHormone-Resistant Prostate NeoplasmsPain +[9] 
Global Approved IndicationsProstatic Neoplasms
Approved Indications in ChinaProstatic Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2013/05/15
Country/TerritoryCzechiaBelgiumCanada +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAlgeta ASA
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityBayer Pharma AgInstitute For Energy Technology +[8] 
Inactive CompaniesUniversity Medical Center FreiburgDuke UniversityThe University Of Texas MD Anderson Cancer Center
Active IndicationsBone metastasesPainProstatic Neoplasms, Castration-Resistant +[5] 
Inactive IndicationsHormone-Resistant Prostate NeoplasmsNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[4] 

Other Information

ATC CodeV10XX03
Related LinksWikipediaDrugBankKEGG